Loading...
•
Sep 30, 2022
Mersana Q3 2022 Earnings Report
Mersana reported financial results for the third quarter of 2022 and provided a business update.
Key Takeaways
Mersana Therapeutics reported its Q3 2022 financial results, highlighting advancements in UpRi, expansion of the clinical pipeline, and strengthened balance sheet through partnerships.
Approximately 270 patients were enrolled in UPLIFT within one year.
UP-NEXT, a randomized Phase 3 clinical trial, was initiated.
Recent collaborations reflect progress in advancing innovative platforms.
The company believes accomplishments strengthen foundation and will enable entry into 2023 with momentum.
Forward Guidance
This press release contains forward-looking statements regarding the therapeutic potential of Mersana’s product candidates, the potential of Mersana’s platforms and technology, the design, progression, timing and objectives of Mersana’s clinical trials and the release of data from those trials, including UPLIFT
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...